Frederick Vogt is Interim Chief Executive Officer and President, General Counsel of Iovance Biotherapeutics, Inc. (IOVA). The company reported total compensation of $1,888,175 for fiscal year 2025.
| Salary | $800,000 |
|---|---|
| Bonus | $0 |
| Stock awards | $759,375 |
| Option awards | $0 |
| Non-equity incentive plan | $312,000 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $16,800 |
| Total | $1,888,175 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Iovance Biotherapeutics, Inc. filed April 28, 2026, accession 0001104659-26-050458.
| Peer-group chief executive median | $7,678,477 |
|---|---|
| Difference from that median | $-5,790,302 |
| Percentile within the disclosed peer group | 1st |
| Peers with a disclosed figure | 11 |
Medians and percentiles are computed across the peer group Iovance Biotherapeutics, Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Daniel Kirby | Chief Commercial Officer | $2,160,595 |
| Frederick Vogt this page | Interim Chief Executive Officer and President, General Counsel | $1,888,175 |
| Corleen Roche | Chief Financial Officer | $1,455,979 |
| Raj Puri | Chief Regulatory Officer | $1,341,778 |
| Igor Bilinsky | Chief Operating Officer | $1,118,062 |
| Matthew Rosinack | Interim Principal Financial Officer and Principal Accounting Officer | $782,491 |
| Jean-Marc Bellemin | Former Chief Financial Officer | $663,104 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Iovance Biotherapeutics, Inc. compensation brief.
Frederick Vogt's compensation sits inside Iovance Biotherapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.